AddedRisk Factors
•the existence of competing therapies and the potential introduction and success of additional competing therapies (including generic versions of competing therapies) that may be developed successfully by others as a treatment for ATTR-CM and/or hATTR-PN;
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedRisk Factors
•our ability to maintain and increase sales of AMVUTTRA in the face of competitive products and to differentiate AMVUTTRA from competitive products, and the willingness of prescribing physicians and patients to start or continue treatment with AMVUTTRA or to switch from a competing product to AMVUTTRA;
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedRisk Factors
•the analysis by doctors, payors and patients of the cost of AMVUTTRA relative to the perceived benefits and our ability to obtain and sustain favorable access and reimbursement dynamics;
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedRisk Factors
•the size of patient populations with ATTR-CM and hATTR-PN, and the number of patients diagnosed with ATTR-CM and hATTR-PN who may be treated with AMVUTTRA;
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RemovedRisk Factors
•We may have difficulty expanding our operations successfully as we continue our evolution from a U.S.- and Europe-based company primarily involved in discovery, preclinical testing and clinical development into a global company that develops and commercializes multiple drugs in multiple geographies.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
•We expect that results from our and our collaborators’ clinical development activities and the clinical development activities of our competitors will continue to be released periodically and may result in significant volatility in the price of our common stock.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
approved indications of certain of our commercial products, including AMVUTTRA. For example, in August and September 2022, we reported positive safety and efficacy results from the APOLLO-B Phase 3 clinical trial of patisiran, which was designed and powered to evaluate the effects of patisiran on functional capacity and quality of life in patients with ATTR amyloidosis with cardiomyopathy. Despite positive safety and efficacy results from our APOLLO-B clinical trial, in October 2023, the FDA issued a CRL for our sNDA for patisiran for the treatment of ATTR amyloidosis with cardiomyopathy.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
•the timing, receipt and amount of sales milestones and royalties, if any, from our approved products and our product candidates, if and when approved; and
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
Any future outbreaks of pandemics or public health emergencies, may directly or indirectly adversely affect our business, results of operations and financial condition.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
In the future, we may experience disruptions from a pandemic or public health emergency that could impact our business and operations, including our ability to obtain regulatory approval for and successfully commercialize our approved products, and we may not be able to meet expectations with respect to commercial sales as a result. In addition, we may experience decreased patient demand for our approved products if current or potential patients decide to delay treatment as a result of a pandemic or public health emergency. Business interruptions from pandemics or public health emergencies, including staffing shortages, raw material or other supply chain shortages, production slowdowns and disruptions in delivery systems, may also adversely impact the third parties we or our collaborators rely on in the U.S. and abroad to sufficiently manufacture our approved products and to produce product candidates in quantities we require, which may impair our commercialization efforts, our research and development activities and the potential commercialization of our product candidates.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
Additionally, timely completion of preclinical activities and initiation of planned clinical trials are dependent upon the availability of, for example, preclinical and clinical trial sites, researchers and investigators, patients or healthy volunteer subjects available for recruitment and enrollment, and regulatory agency personnel, which may be adversely affected by global health matters, such as any pandemic or public health emergency. Health regulatory agencies globally may also experience disruptions in their operations as a result of a pandemic or future public health emergency, which could impact review, inspection and approval timelines.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
While the ultimate impact of any pandemic or public health emergency on our business is uncertain, any negative impacts of such pandemic or public health emergency, alone or in combination with others, could exacerbate other risk factors discussed herein. The full extent to which any pandemic or public health emergency, will negatively affect our operations, financial performance, and stock price will depend on future developments that are highly uncertain and cannot be predicted.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
In such collaborations, we expect our current, and may expect any future, collaborators to provide substantial capabilities in clinical development, regulatory affairs, and/or marketing, sales and distribution. Under certain of our collaborations, we also
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our collaboration agreement with Roche requires that Roche pay us a milestone payment at the initiation of a Phase 3 clinical trial of zilebesiran. In the event that Roche determines to terminate our collaboration prior to the initiation of a Phase 3 clinical trial of zilebesiran, whether because of data from the earlier clinical development of zilebesiran or for any other reason,
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
we would not receive the Phase 3 milestone from Roche, which could have a material adverse effect on our operating results and financial condition and make it more difficult for us to achieve profitability in 2025. In these circumstances, we would also need to determine whether to continue the clinical development of zilebesiran in the absence of funding and other support from Roche.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedRisk Factors
and any future products and to support our growing research, development and global commercialization efforts and initiatives, which would have an adverse effect on our ability to implement our future business plans.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RewordedRisk Factors
In addition, if we have a dispute with a collaborator over the ownership of technology or other matters, or if a collaborator terminates its collaboration with us, for breach or otherwise, or determines not to pursue the research, development and/or commercialization of the affected product or product candidate, it could delay our development of product candidates, result in the need for additional company resources to develop our product candidates, require us to expend time and resources to develop expanded sales and marketing capabilities on a more expedited timeline, make it more difficult for us to attract new collaborators and adversely affect how we are perceived in the business and financial communities.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, ONPATTRO utilizes an intravenous mode of administration with pre-medication that physicians and/or patients may not readily adopt, AMVUTTRA is administered through a subcutaneous injection and which may not compete favorably with other available options for the treatment of hATTR amyloidosis with polyneuropathy ATTR-CM, including VYNDAQEL/VYNDAMAX, which is marketed by Pfizer and administered in pill form, and ATTRUBY, which is marketed by BridgeBio and administered in pill form, or other available options for the treatment of hATTR-PN in adults, including WAINUA (eplontersen), WAINUA, which is marketed by AstraZeneca and Ionis, and administered subcutaneously, or tafamidis, VYNDAQEL/VYNDAMAX, which is marketed by Pfizer in several countries and administered in pill form.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Analogous We are also subject to state and foreign laws and regulations, such as comparable to the above federal laws, including state anti-kickback, anti-bribery and false claims laws, which may apply to healthcare items or services that are reimbursed by non-governmental third-party payors, including private insurers, as well as other insurers; state laws that require companies to comply with specific compliance standards, restrict financial interactions between companies and healthcare providers, require companies to report information related to payments to healthcare providers, marketing expenditures or pricing or require the licensing or registration of sales representatives. representatives; and EU laws prohibiting giving healthcare professionals any gift or benefit in kind as an inducement to prescribe our products and transparency laws requiring the public disclosure of payments made to healthcare professionals and institutions, and data privacy laws.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although to date we have launched four products in the U.S., EU and various other countries globally, and expect to launch our commercially approved products products, including AMVUTTRA in patients with ATTR amyloidosis with cardiomyopathy, in additional countries during 2026 and in subsequent years, and have two marketed products being commercialized by our collaborators, we achieved profitability for the first time in fiscal year 2025 and beyond, and have one marketed product that is commercialized by a collaborator, we may not achieve or be able to sustain profitability or positive cash flow from operations.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
To execute our business plan of building a profitable, top-tier biotech company by the end of 2025 achieving leadership in ATTR amyloidosis, driving sustainable innovation, and achieving delivering sustained, profitable growth under our Alnylam P5x25 strategy and the metrics associated with such 2030 strategy, in addition to successfully marketing, launching, marketing and selling our TTR products and expanding the approved indications of our other approved products, we will also need to successfully:
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
(a subsidiary of AstraZeneca) and is in Phase 3 clinical development; coramitug (NNC-6019-0001), YOLT-201 which is being developed by Novo Nordisk YolTech and is in Phase 2 clinical development; development (China only); and AT0-2, AT-02, which is being developed by Attralus, Inc. and is in Phase 2 1 clinical development. development; and BPR-30221616, which his being developed by Chengdu Beite Pharma and is in Phase 1 clinical development (China only).
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we are not able to attract and retain highly qualified sales and marketing, research, development, and other professionals, it would negatively impact our ability to commercialize our approved products and any future products and to support our growing research and development and global commercialization efforts and initiatives, which would have an adverse effect on our ability to implement our future business plans and to achieve the goals of our Alnylam 2030 strategy.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
The marketing and sale of our approved products products, including AMVUTTRA for ATTR amyloidosis with cardiomyopathy, or any future products for which we or our collaborators receive regulatory approval may be unsuccessful or less successful than anticipated, and we may be unable to expand the approved indications for certain of our commercial products, including AMVUTTRA. anticipated.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
While we believe our current cash, cash equivalents and marketable equity and debt securities, as well as the revenue we expect to generate from product sales and under our existing collaborations, including milestones and royalties on sales of Leqvio sales, and Qfitlia, and cemdisiran, if approved, should enable us to achieve a self-sustainable profile by the end of 2025 without the need for future equity financing, sustain operating profitability, we also will depend on our ability to generate incremental product, collaboration and royalty revenues to achieve this goal.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although we have commercially launched four products and have an two additional product products being commercialized by a collaborator, our collaborators, we cannot predict whether we will successfully market and sell our approved products, or successfully expand including AMVUTTRA, which was launched in the U.S. for the treatment of ATTR amyloidosis with cardiomyopathy following FDA approval in March 2025.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Further, from time to time we issue financial guidance relating to our expectations regarding our combined net product sales, revenues (both for our TTR products and for all of our approved products), collaboration and royalty revenues, and GAAP and non-GAAP combined research and development and selling, general and administrative expenses, which guidance is based on estimates and the judgment of our management. expenses.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, due to a routine inspection by the FDA at a CMO facility that resulted in a pending inspection classification, we amended our regulatory submission for vutrisiran for the treatment of hATTR-PN in adults, which delayed our PDUFA action date and AMVUTTRA’s initial NDA approval with the FDA.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Accordingly, we have entered into collaborations with third party collaborators we believe can provide such capacity and capabilities in certain territories and/or for certain product candidates, and we intend to may enter into additional such collaborations in the future.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
As a result of Regeneron’s opt-out, we have full development and commercialization rights to mivelsiran in all indications but we will be are responsible for funding further development and commercialization of mivelsiran, including the ongoing Phase 2 development program, without funding from Regeneron.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Specifically, we have stated that we will not raise the price of any product for which we receive marketing approval over the rate of inflation, as determined by the consumer price index for urban consumers (approximately 3.5% currently) absent a significant value driver.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
We achieved profitability for the first time in 2025, with full-year net product revenues of approximately $3.0 billion, driven primarily by strong growth in our TTR franchise. Nevertheless, we have incurred significant losses since inception and, as of December 31, 2025, we had an accumulated deficit of $6.70 billion. Historically, we generated losses primarily from costs associated with research and development activities; acquiring, filing and protecting our intellectual property rights; and selling, general and administrative activities. With the achievement of profitability in 2025, going forward we expect to be able to fund our operations primarily from product revenues, which we expect will be supplemented by collaboration revenue and royalty revenue from products commercialized by our collaborators.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
We expect to continue investing significantly in research and development to advance our RNAi platform and clinical pipeline. These planned expenditures include costs associated with our activities as we (i) progress our late-stage programs, including the Phase 3 TRITON-PN and TRITON-CM clinical trials of nucresiran (our next generation TTR silencer) in patients with hATTR-PN and ATTR-CM, respectively, and the Phase 3 ZENITH cardiovascular outcomes trial of zilebesiran in patients with uncontrolled hypertension, all three of which we initiated in 2025; (ii) progress our early stage clinical pipeline, including CNS and metabolic programs; (iii) continue our efforts to deliver RNAi therapeutics to additional tissues and to treat new disease areas; and (iv) selectively pursue complementary modalities through business development.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
Through these investments, we plan to expand our efforts to discover, develop and commercialize the next wave of RNAi therapeutics and aim to achieve the goals associated with our Alnylam 2030 strategy. These goals include expanding to 10 tissue types and more than 40 clinical programs, delivering at least two new transformative medicines beyond TTR with blockbuster potential, investing approximately 30% of our revenues in non-GAAP R&D (including select external innovation), achieving 25%+ total revenue compound annual growth rate, and delivering approximately 30% non-GAAP operating margin through year-end 2030.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
Given the significant and growing contribution of AMVUTTRA to our total product revenues following regulatory approvals of AMVUTTRA for the treatment of ATTR-CM, our cost of goods sold, operating income and operating margin in 2025 were significantly impacted by the royalties we pay to Sanofi on global sales of AMVUTTRA under our TTR license agreements, and we expect this will continue in future years. Sanofi is eligible to receive tiered royalties on global annual net sales of AMVUTTRA across all indications in the following tiers: 15% of global annual net sales of $0 to $150.0 million; 17.5% of global annual net sales greater than $150.0 million to $300.0 million; 20% of global annual net sales greater than $300.0 million to $500.0 million; 25% of global annual net sales greater than $500.0 million to $1.50 billion; and 30% of global annual net sales in excess of $1.50 billion. There are no royalties owed on nucresiran, our next-generation investigational RNAi therapeutic, which is currently in development for the treatment of ATTR amyloidosis. Assuming successful development and regulatory approval, we believe that with its anticipated product profile, nucresiran has the potential to become a leading therapy for ATTR amyloidosis and to significantly improve our gross margins on product sales and our non-GAAP operating income margin.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
Net product revenues, classified based on the geographic region in which the product is sold and by franchise (“TTR,” which includes AMVUTTRA and ONPATTRO, and “Rare,” which includes GIVLAARI and OXLUMO) consisted of the following:
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
Net revenues from collaborations and royalty revenue consisted of the following:
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
•recognition of a $30.0 million payment in connection with the amendment to our agreement with Vir Biotechnology in March 2025.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
•revenue recognized under our license agreement with Novartis associated with the achievement of a specified Leqvio commercialization milestone during the year ended December 31, 2024.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
•increased clinical trial expenses for the ZENITH Phase 3 clinical trial of zilebesiran, the TRITON-CM Phase 3 clinical trial of nucresiran in patients with ATTR-CM and the TRITON-PN Phase 3 clinical trial of nucresiran in patients with hATTR-PN;
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
•increased interest expense associated with the vutrisiran and zilebesiran development funding liabilities as a result of the adoption of ASU 2025-07; and
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
•loss related to convertible debt representing an inducement expense in connection with the partial repurchases of our 1.00% Convertible Senior Notes due 2027, or the 2027 Notes, in September and December 2025.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
AddedMD&A
During the year ended December 31, 2025, net cash used in financing activities was $305.2 million, whereas during the year ended December 31, 2024 net cash provided by financing activities was $294.2 million. This was primarily due to $1.15 billion paid for the repurchase of $672.2 million aggregate principal amount of our 2027 Notes during the year ended December 31, 2025, partially offset by $645.7 million of net proceeds from our offering of the 0.00% Convertible Senior Notes due 2028 in the aggregate principal amount of $661.3 million, $35.3 million of which was used to pay the cost of the related capped call transactions. Additionally, we collected lower net proceeds from the issuance of common stock in connection with stock option exercises during the year ended December 31, 2025, as compared to the year ended December 31, 2024.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RemovedMD&A
•a decrease in revenue recognized under our Roche Collaboration in 2024 due to the recognition of $310.0 million of revenue upon the transfer of licenses to Roche during the third quarter of 2023.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
product manufacturing as our collaborators transition to producing the material independently, as well as reduced royalties payable from the expiration of licenses of third-party intellectual property.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
•increased clinical trial expenses mainly related to the advancement of our KARDIA-3 and cAPPRicorn-1 clinical programs;
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
•increased costs associated with our preclinical activities as we develop our clinical pipeline of RNAi therapeutics targeting multiple tissue types;
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
•increased stock-based compensation expenses primarily due to the accounting for certain performance-based awards.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
•decreased costs due to the timing of manufacturing of zilebesiran for clinical activities.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
During the years ended December 31, 2024, 2023 and 2022, in connection with advancing activities under our collaboration agreements, we incurred research and development expenses, primarily related to external development and clinical expenses, including the manufacture of clinical product. The following table summarizes research and development expenses incurred, for which we recognize revenue, that are directly attributable to our collaboration agreements, by collaborator:
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
Total other expense, net increased during the year ended December 31, 2024, as compared to the year ended December 31, 2023, primarily due to increased loss associated with the change in fair value of the development derivative liability as a result of valuation updates driven by the positive topline results for the HELIOS-B clinical trial announced in June 2024, partially offset by increased interest income driven by higher market interest rates on our marketable debt securities.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
Years Ended December 31, 2024 vs 2023 2023 vs 2022 (In thousands, except percentages) 2024 2023 2022 $ Change % Change $ Change % Change Benefit from (provision for) income taxes $ 99,218 $ (6,725) $ (4,163) $ 105,943 * $ (2,562) 62% * Indicates the percentage change period over period is greater than 500%.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
cardiomyopathy and the first commercial sale of AMVUTTRA following regulatory approval of AMVUTTRA for the treatment of ATTR amyloidosis with cardiomyopathy, respectively, within the next 12 months.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
In August 2020, we entered into a co-development agreement, referred to as the Funding Agreement, with BXLS V Bodyguard – PCP L.P. and BXLS Family Investment Partnership V – ESC L.P., collectively referred to as Blackstone Life Sciences, pursuant to which Blackstone Life Sciences will provide up to $150.0 million in funding for the clinical development of vutrisiran and zilebesiran, two of our cardiometabolic programs. As consideration for Blackstone Life Sciences’ funding for certain vutrisiran and zilebesiran clinical development costs, we have agreed to pay Blackstone Life Sciences fixed success-based payments upon achievement of specific milestones for vutrisiran and zilebesiran as well as a 1% royalty on net sales of vutrisiran for ten years.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RemovedMD&A
The development derivative liability is recorded at fair value and represents our current estimate of the expected future payments to Blackstone Life Sciences. The development derivative liability is based on the probability weighted present value of the estimated cash flows pursuant to contractual terms of the Funding Agreement. The most significant assumptions in determining the development derivative liability are the probability of success for the clinical development and regulatory approval of vutrisiran and zilebesiran and our current cost of borrowing. Estimates of the probability of success and our cost of borrowing are based on what we believe to be reasonable and supportable assumptions and require management’s judgment. Actual results could vary materially from these estimates.
Read it in 10-K Feb 13, 2025 at sec.govopen_in_new
RewordedMD&A
We expect our cost of goods sold, including cost Cost of goods sold as a percentage of net product revenues, will increase during revenues increased to 22.7% for the year ended December 31, 2025, as compared to 18.6% for the year ended December 31, 2024, primarily as a result of increased sales of AMVUTTRA and an expected associated increase in net product revenues and increased royalties the blended royalty rate payable on net sales of AMVUTTRA.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
Selling, general and administrative expenses increased during the year ended December 31, 2024, 2025, as compared to the year ended December 31, 2023, 2024, primarily due to higher costs employee compensation costs, including stock-based compensation, mainly driven by higher headcount, and increased marketing investment associated with marketing investments to promote our TTR therapies and prepare for the potential commercial launch of AMVUTTRA for the treatment of ATTR amyloidosis with cardiomyopathy and increased employee compensation expenses. in ATTR-CM.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
Net product revenues increased during the year ended December 31, 2024, 2025, compared to the year ended December 31, 2023, 2024, primarily due to growth from sales of AMVUTTRA revenues driven by increased patient demand, mainly in patients with ATTR-CM in the U.S., which was partially offset by a decrease in sales decreased number of ONPATTRO patients on ONPATTRO, and due to patient switches to AMVUTTRA, as well as growth from an increased number of patients on GIVLAARI and OXLUMO therapies. OXLUMO.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
Based on our current operating plan, we believe that our cash, cash equivalents equivalents, marketable securities, as well as the revenue we expect to generate from product sales and marketable securities under our existing collaborations, including royalties on sales of Leqvio and Qfitlia, and available borrowing capacity under the revolving credit agreement as of December 31, 2024 2025 will be sufficient to satisfy our near-term capital and operating needs for at least 12 months from the filing of this Annual Report on Form 10-K.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
We recorded a provision for income taxes of $9.4 million for the year ended December 31, 2025 and a benefit from income taxes of $99.2 million for the year ended December 31, 2024 and a provision for income taxes of $6.7 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
We expect net revenues from collaborations will increase decrease in 2025, 2026, as compared to 2024, primarily driven by higher anticipated revenues 2025, due to the $300.0 million of milestone revenue that we recognized under our Roche Collaboration and License Agreement. Agreement in the year ended December 31, 2025.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
However, we and our ongoing development and regulatory efforts may not be successful and we collaborators may not be able to commence sales of any other products and/or successfully expand the labels of or market and sell our existing commercialized products or any other approved products in the future.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
However, Moreover, our ongoing development and regulatory efforts may not be successful successful, and we and our collaborators may not be able to commence sales of any other products and/or successfully expand the labels of or market and sell our existing commercialized products or any other approved products in the future.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
We expect that research and development expenses combined with selling, general and administrative expenses will increase during 2025, 2026, as compared to 2024, 2025, as we continue to build out our global commercial and compliance infrastructure, launch our current commercial products into new markets, prepare for future commercial product launches, including the continued launch of AMVUTTRA in cardiomyopathy, assuming regulatory approvals, for the treatment of ATTR-CM, advance our product candidates, including collaborated programs, into later-stage development, advance and develop our platform and preclinical pipeline, and prepare regulatory submissions.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
We For the year ended December 31, 2025, we maintained a full valuation allowance on against our U.S. net deferred tax assets as of December 31, 2024. in the U.S.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
We expect our cost of goods sold, including cost of goods sold as a percentage of net product revenues, will increase during 2025, 2026, as compared to 2024, 2025, primarily as a result of an expected increase in net product revenues sales of AMVUTTRA and increased royalties an associated increase in the royalty rate payable on net sales of AMVUTTRA.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new
RewordedMD&A
We currently have programs focused on a number of therapeutic areas and, as As of December 31, 2024, 2025, we generate worldwide product revenues from our four commercialized products, AMVUTTRA, ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO, primarily in the U.S. and Europe.
Read it in 10-K Feb 12, 2026 at sec.govopen_in_new